Matthew A. Pearson litigates patent cases across a range of technologies, including pharmaceuticals, chemistry, biotechnology and medical devices, with a particular focus on biologics and antibody technology.

Practice & Background

Dr. Pearson has extensive trial experience in biologics and immunology patent cases.

For example, in the field of immunooncology, Dr. Pearson represented Bristol-Myers Squibb Ono Pharmaceuticals, and Professor Tasuku Honjo in their patent infringement case against Merck & Co.  The worldwide settlement for the plaintiffs included an initial payment by Merck of $625 million and ongoing royalties through 2026.

Dr. Pearson was part of the trial team that won a jury verdict for client Janssen Biotech Inc. in a patent infringement case brought by Abbott GmbH & Co. In that case, the jury returned a verdict that claims in two patents asserted against Janssen’s antibody drug product Stelara®were invalid. Dr. Pearson was responsible for direct and cross examination of technical experts. The judgment was affirmed on appeal.Dr. Pearson was part of the trial team that won a $1.67 billion verdict on behalf of Centocor Ortho Biotech, Inc. and New York University. That case involved an infringement suit against Abbott Laboratories for its blockbuster drug Humira®. The jury returned a verdict finding the patent-in-suit willfully infringed and not invalid. Bloomberg reported the $1.67 billion verdict as the largest patent jury verdict in U.S. history.

Dr. Pearson served for two years as a law clerk to the Honorable Kent A. Jordan of the U.S. District Court for the District of Delaware and the U.S. Court of Appeals for the Third Circuit.

Dr. Pearson earned his J.D., summa cum laude, from the University of Pennsylvania Law School, where he was an editor of the Law Review, a James Wilson Fellow in Law and Technology, and a member of the Order of the Coif. He earned his Ph.D. in biochemistry from Cornell University and B.S. degrees in chemistry and biochemistry from Michigan State University. His scientific work focused on the mechanism and three-dimensional molecular structures of enzymes and cell signaling proteins using x-ray crystallography.

Dr. Pearson is an adjunct professor at the University of Pennsylvania Law School, where he has taught courses in patent litigation and in trademark law. He is also a frequent speaker on trial advocacy and patent litigation strategy, particularly for pharmaceutical and biotechnology cases.

Representative Matters

Dr. Pearson’s other recent cases include:

  • representing pharmaceutical companies in patent infringement cases against multiple defendants related to immunooncology methods (D. Del.)
  • representing pharmaceutical companies in a case seeking correction of inventorship for immunooncology patents (D. Mass.)
  • representing pharmaceutical company in ANDA litigation related to synthesis of pharmaceutical ingredients (D. Del.)
  • represented biotechnology company in a patent infringement case related to DNA analysis tools (D. Del.)
  • represented university in inter partes reviews relating the DNA analysis tools
  • represented pharmaceutical company in patent infringement case related to antibody therapies (D. Mass.), resulting in a favorable settlement.
  • represented pharmaceutical companies in ANDA litigation related to synthesis of pharmaceutical ingredients, resulting in a win at trial (S.D.N.Y.) and on appeal
  • represented medical device company in a patent infringement case related to surgical devices (D. Conn.), resulting in favorable judgment
  • represented pharmaceutical company in patent infringement case related to antibody production methods (C.D. Cal.), resulting in a favorable settlement.

Awards & Accolades

  • Dr. Pearson has been named in Super Lawyers (2013-2016) and as a “Rising Star” in the field of intellectual property litigation (2010-2012).